novo nordisk insulin - Search News

Novo Nordisk shares drop

Reuters on MSN · 2d

Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely on the lower-than-expected weight loss.

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

Fox Business on MSN · 2d

Novo Nordisk shares fall on weight-loss drug trial

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Fierce Pharma2d

Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

2d

Hikma looks to launch generic versions of Novo Nordisk diabetes drugs, FT says

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...

2d

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results